Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProButyrate is a dietary supplement developed by Tesseract Medical Research (sometimes referred to as Tesseract Medicines) that utilizes proprietary CyLoc and DexKey technologies to deliver butyric acid throughout the gastrointestinal tract. Butyric acid is a short-chain fatty acid (SCFA) that serves as a primary energy source for the cells lining the colon (colonocytes) and plays a crucial role in maintaining gut barrier integrity and a balanced microbiome. The CyLoc technology employs a molecular trap to encapsulate the butyric acid, while the DexKey release agent ensures its sustained release and solubility in the large intestine, effectively masking the ingredient's characteristic strong odor and taste. It is marketed for gut health, digestive support, and neurological well-being.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ProButyrate.